High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer
Clinical Breast Cancer, ISSN: 1526-8209, Vol: 13, Issue: 2, Page: 103-108
2013
- 30Citations
- 37Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations30
- Citation Indexes30
- 30
- CrossRef20
- Captures37
- Readers37
- 37
- Mentions1
- References1
- Wikipedia1
Article Description
Expression of class ΙΙΙ β−tubulin (βΙΙΙ-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βΙΙΙ-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. We determined βΙΙΙ-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βΙΙΙ-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. High βΙΙΙ-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers ( P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/ neu overexpression. In ER – tumors treated with neoadjuvant chemotherapy, high βΙΙΙ-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores ( P =.021). This study reveals differential βΙΙΙ-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/ neu status. It also suggests a potential role for βΙΙΙ-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER – breast cancer, which has not been previously reported. These data provide a strong rationale for considering βΙΙΙ-tubulin status and further validation of this marker in a large study.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1526820912002595; http://dx.doi.org/10.1016/j.clbc.2012.11.003; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84875182273&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23218766; https://linkinghub.elsevier.com/retrieve/pii/S1526820912002595; http://www.clinical-breast-cancer.com/article/S1526-8209(12)00259-5/abstract; http://www.clinical-breast-cancer.com/retrieve/pii/S1526820912002595; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.clinical-breast-cancer.com%2Fretrieve%2Fpii%2FS1526820912002595&rc=0&code=clbc-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.clinical-breast-cancer.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaaeo0a_7TVZL7KalLTxv%2526MAID%253DoY7Rt8lkEWets8qLPzV%25252FWw%25253D%25253D%2526SERVER%253DWZ6myaEXBLGliB%25252BRW%25252F74SA%25253D%25253D%2526ORIGIN%253D941239582%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.clinical-breast-cancer.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaaeo0a_7TVZL7KalLTxv%2526MAID%253DoY7Rt8lkEWets8qLPzV%25252FWw%25253D%25253D%2526SERVER%253DWZ6myaEXBLGliB%25252BRW%25252F74SA%25253D%25253D%2526ORIGIN%253D941239582%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.clinical-breast-cancer.com%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaaeo0a_7TVZL7KalLTxv%26MAID%3DoY7Rt8lkEWets8qLPzV%252FWw%253D%253D%26SERVER%3DWZ6myaEXBLGliB%252BRW%252F74SA%253D%253D%26ORIGIN%3D941239582%26RD%3DRD&acw=&utt=; http://linkinghub.elsevier.com/retrieve/pii/S1526820912002595
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know